Stock APLT APPLIED THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.28 USD +1.18% Intraday chart for Applied Therapeutics, Inc. -2.28% +27.76%
Apr. 15 Applied Therapeutics, Inc. Announces Management Changes CI
Mar. 28 Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
GL
Applied Therapeutics, Inc. Announces Management Changes
CI
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
GL
Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review
DJ
FDA Extends Review Period for Applied Therapeutics Genetic Disease Treatment
DJ
Applied Therapeutics Gets NDA Review Period Extension for Galactosemia Treatment -- Shares Fall After Hours
MT
US FDA extends review of Applied Therapeutics' genetic disease drug
RE
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
GL
Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
CI
RBC Initiates Applied Therapeutics at Outperform, Speculative Risk With $12 Price Target, Sees Lead Drug Govorestat 'Well-Positioned for Success'
MT
UBS Adjusts Applied Therapeutics Price Target to $13 From $12, Maintains Buy Rating
MT
UBS Adjusts Applied Therapeutics Price Target to $12 From $4, Maintains Buy Rating
MT
Applied Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (APLT) APPLIED THERAPEUTICS Reports Q4 Revenue $10M
MT
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
GL
Applied Therapeutics, Inc. announced that it has received $99.997998 million in funding from a group of investors
CI
Applied Therapeutics' NDA for Govorestat Accepted by FDA; Launches $100 Million Private Placement; Shares Jump
MT
Applied Therapeutics Shares Surge on FDA Review, $100 Million Funding Round
DJ
Applied Therapeutics Announces $100 Million Private Placement
GL
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLT Stock
  4. News Applied Therapeutics, Inc.